Background: Acute myeloid leukemia (AML) is characterized by genetic heterogeneity, poor overall survival (OS), and variable treatment responses. FLT3 gene mutations are among the most frequently reported in AML, with ~ 25% of patients (pts) with newly diagnosed (ND)...
In intensively treated acute myeloid leukemia (AML) patients, measurable residual disease (MRD) has become a critical standardized endpoint which is highly predictive of relapse-free (RFS) and overall (OS)survival. Azacitidine and venetoclax (AZA/VEN) combination...
KMT2A rearrangements (KMT2Ar) occur in ~5% of adult AML and their outcomes are generally poor, with high rates of early relapse. Menin inhibitors have shown encouraging activity in relapsed/refractory disease, and trials combining these agents with intensive...
BackgroundFLT3-ITD mutations are found in approximately one quarter of patients with acute myeloid leukemia (AML). One major change in the 2022 ELN risk classification is the re-classification of all FLT3-ITD mutated patients as intermediate risk independently of...
Background:FLT3-TKD mutations are present in 7-10% of newly diagnosed AML. However, its prognostic impact remains poorly defined, especially in the current treatment landscape, wherein FLT3-inhibitors (FLT3i) and venetoclax (VEN) are often used in frontline regimens....
Recent Comments